Appointments

866.320.4573

Request an Appointment

Questions

800.223.2273

Contact us with Questions

Expand Content

Research & Innovations

The physicians and scientist in the Endocrine & Metabolism Institute are committed to doing research that advances the treatment of diseases and improves the care of patients. These studies include investigations of new treatments for diabetes and other endocrine disorders, newer surgical approaches to parathyroid and thyroid conditions radiofrequency ablation of liver tumors, and surgical and medical management of obesity.

A brief description of our research projects that are actively enrolling new subjects is listed below. Should you desire any further information about our research program or interested in participating in one of our research studies, please contact:

Denise Rose
Research Coordinator
rosed2@ccf.org
216.444.8824

A phase and multicenter study designated to evaluate the efficiency and safety of a long acting hGH product in adult subjects with growth hormone deficiency

Inclusion:

  • Men and women between the ages of 23 and 70 years old
  • No r-hGH replacement therapy or use of GH secretagogues for at least 9 months with any registered or investigational r-hGH or GH secretagogue product
  • Body Mass Index (BMI, kg/m) of 23.0 to 35.0 kg/m, both inclusive

Study Contact
Alyssa Mackie
216.444.8942

Metabolic Components of Osteoarthritis in Diabetes and Obesity

Inclusion:

  • Previous diagnosis of knee osteoarthritis and experiencing knee pain or stiffness
  • Obese (BMI of 30-50 kg/m2) with or without type 2 diabetes or lean (BMI of 18.5-24.9 kg/m2)

Study Contact
Mia Williams
216.444.7551

The ENDO Trial - A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Metformin and/or Sulfonylurea Anti-Diabetes Agents

Inclusion:

  • Ages between 21 and 65
  • Diagnosis of type 2 diabetes for less than 20 years
  • HbA1c greater than 7.5% and less than 10%

Exclusions: Abnormal pathologies or conditions of the gastrointestinal tract, including current ulcers of Crohn's disease, history of atresias of untreated stenoses, and current upper gastro-intestinal bleeding conditions within 3 month of randomization.

Study Contact
Ana Surckla
216.444.3955

Gastric Plication for the Treatment of Obesity and Related Conditions
  • 18 years old or older
  • PaBMI of < 27 with one or more significant co-morbid medical conditions
  • Ability of self-pay or pay any co-payments for the procedure and follow up

Study Contact
Chytaine Hall
216.445.3983

Post Marketing Surveillance Study of Somavert Therapy in Patients with Acromegaly
  • A pituitary imaging study performed within six months prior to start of Somavert or Acrostudy start if patient is already on Somavert treatment

Study Contact
Andreea Mocanu
216.444.9612

Exenatide Study of Cardiovascular Event Lowering Trial
  • Age 18 years or older
  • Patients with Type 2 Diabetes
  • HgbA1c 6.5% - 10% within 3 months of screening
  • Up to three oral anti-hypertension agents or insulin with up to two oral anti-hypertension agents

Study Contact
Robert McCoy
216.445.4029

ACTH Stimulation Test with 25 ug Cortrosyn for Evaluation of Adult Hypothalamic Pituitary Adrenal Axis
  • Age 18 to 65 years old
  • Patients with hypothalamic pituitary adrenal disorders
  • At least three months of stable hormone replacement therapy for hormone deficiencies
  • Also seeking healthy volunteers

Study Contact
Robert McCoy
216.445.4029

Parathyroid Decrease and Artery Evaluation-Effects of Parathyroidectomy in Reducing Coronary Artery Calcification and Improving Vascular Compliance
  • 18 years or older
  • Primary or secondary hyperparathyroidism scheduled for parathyroid surgery

Study Contact
Josephine Chan
216.445.7488

Parathyroid Surgery Comparison Study-Prospective Randomized Comparison of Bilateral vs. Focal Neck Exploration for Sporadic Hyperparathyroidism
  • 18 years or older
  • Diagnosis of Sporadic Primary Hyperparathyroidism

Study Contact
Mario Scarcipino 
216.444.3599

Cortendo - An open label study to assess the safety and efficacy of COR-003 (2S, 4R-Ketoconazole) in the treatment of endogenous Cushing's syndrome

Inclusions:

  • Confirmed diagnosis of persistent or recurrent CS (with or without therapy) or newly diagnosed disease, if they are not candidates for surgery
  • Subjects on treatment for CS for whom treatment has been inadequate or not well tolerated
  • 12-lead ECG’s show no acute ischemia or clinically significant abnormality needing medical intervention
  • Exclusion criteria-History of malignancy & subjects treated with radiation within the previous 4 years or > 4 years with evidence of improvement in their disease within 6 months prior to screening

Study Contact:
Andreea Mocannu
216.444.9612

D2d Study - Randomized (1:1) double-masked, placebo-controlled, parallel-group, primary prevention clinical trial with 2 arms (oral daily vitamin D vs. placebo) in participants at high risk for diabetes (with pre-diabetes) who will be followed for approx. 4 years after randomization for incident diabetes

Inclusions:

  • Age 30 or greater
  • Fasting plasma glucose 100-125 mg/dl
  • 2 hour plasma glucose 140-199 mg/dl
  • HgbA1c 5.7-6.4%
  • BMI 24-42 kg/m2

Study Contact:
Alyssa Mackie
216.444.8942

Genkyotex - Study evaluating the safety and efficacy of oral GKT137831 in patients with Type 2 Diabetes and Albuminuria

Inclusions:

  • Age 18 to 80 years
  • Patients with type 2 diabetes
  • HgbA1c <11%
  • Albuminuria defined as a UACR of 300 to 3500 mg/g
  • eGFR>30

Study Contact:
Bob McCoy
216.445.4029

Schedule an Appointment Online

Call us for an Appointment

  • To find an endocrinologist or diabetes specialists for your needs, contact the Endocrinology & Metabolism Institute at 216.444.6568 (or toll-free 1.800.223.2273, ext. 46568).
  • To find a bariatric surgeon, contact the Bariatric and Metabolic Institute at 800.339.9829.

Same-day Appointments

To arrange a same-day visit, call 216.444.CARE (216.444.2273).

This information is provided by Cleveland Clinic and is not intended to replace the medical advice of your doctor or health care provider. Please consult your health care provider for advice about a specific medical condition.

© Copyright 2014 Cleveland Clinic. All rights reserved.